TARS
NASDAQTarsus Pharmaceuticals Inc.
Price$64.48+0.36 (+0.56%)
01:30 PM02:00 PM
News · 26 weeks77+44%
2025-12-282026-06-21
Mix2990d
- Insider11(38%)
- Other8(28%)
- SEC Filings6(21%)
- Earnings2(7%)
- Analyst1(3%)
- Offering1(3%)
Latest news
25 items- INSIDERPresident/CEO and Board Chair Azamian Bobak R. sold $615,488 worth of shares (10,000 units at $61.55) as part of a pre-agreed trading plan (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDEROfficer Farrow Jeffrey S converted options into 27,881 shares and sold $877,436 worth of shares (14,396 units at $60.95), increasing direct ownership by 31% to 56,801 units (SEC Form 4) (withholding tax)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Goodrich Katherine sold $183,384 worth of shares (2,954 units at $62.08) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 2,233 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Link William J Phd sold $776,495 worth of shares (12,500 units at $62.12) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 106,786 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- INSIDERDirector Morrison Scott W converted options into 2,954 shares, increasing direct ownership by 63% to 7,638 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Chaudhuri Bhaskar converted options into 2,954 shares, increasing direct ownership by 34% to 11,654 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Yarno Wendy L converted options into 2,954 shares, increasing direct ownership by 22% to 16,654 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Goodrich Katherine converted options into 2,954 shares, increasing direct ownership by 132% to 5,187 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Link William J Phd converted options into 2,954 shares, increasing direct ownership by 3% to 119,286 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Goldberg Andrew D. converted options into 2,954 shares, increasing direct ownership by 18% to 19,654 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- PRAchieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of DirectorsSEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat
- PRTarsus to Participate in Upcoming Investor ConferencesIRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 46th Annual Growth Stock Conference on Tuesday, June 2nd, at 8:00 a.m. PT / 11:00 a.m. ET.2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd, at 8:40 a.m. PT / 11:40 a.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and
- SECSEC Form SCHEDULE 13G filed by Tarsus Pharmaceuticals Inc.SCHEDULE 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- PRTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million AmericansCena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around the eyelashesThis common and often overlooked condition is characterized by eyelid redness, itching and crusting, and the collaboration encourages people to prioritize their eye health IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by microscopic mites that live in and around the eyelashes. Cena's story reflects the experience of millions who live with symptoms
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- PRTarsus to Participate in Upcoming Investor ConferencesIRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2026 Health Care Conference on Tuesday, May 12th, at 3:40 p.m. PT / 6:40 p.m. ET.H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19th, at 8:00 a.m. PT / 11:00 a.m. ET.Stifel 2026 Virtual Ophthalmology Forum on Tuesday, May 26th, at 12:30 p.m. PT / 3:30 p.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECSEC Form 10-Q filed by Tarsus Pharmaceuticals Inc.10-Q - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- PRTarsus Reports First Quarter 2026 Financial Results and Recent Business AchievementsGenerated first quarter XDEMVY® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion Nearly half of core eye care professionals are prescribing XDEMVY weekly, driven by deeper utilization, increased patient demand through Direct-to-Consumer campaign, and ongoing evidence generation Initiated Calliope, a Phase 2 trial of TP-05, a novel investigational oral tablet for the potential prevention of Lyme disease, with topline data expected in the first half of 2027 Management to host conference call today, May 6, 2026, at 1:30 p.m.
- PRTarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to ad
- INSIDERDirector Pyott David E I converted options into 1,383 shares (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SECSEC Form DEFA14A filed by Tarsus Pharmaceuticals Inc.DEFA14A - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
TARS FAQ
7 questionsWhat does Tarsus Pharmaceuticals Inc. do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in...Where does TARS stock trade?
Tarsus Pharmaceuticals Inc. (TARS) is listed on NASDAQ.What sector and industry is TARS in?
Tarsus Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Tarsus Pharmaceuticals Inc. go public?
Tarsus Pharmaceuticals Inc. (TARS) completed its IPO in 2020.What are analysts saying about TARS?
Tarsus Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform on 2026-04-24. Recent price targets range from $1900.00 to $4400.00.What companies are similar to TARS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare TARS side-by-side with any of them on Quantisnow.How can I track TARS on Quantisnow?
Quantisnow aggregates Tarsus Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TARS to receive live email and push alerts on every new disclosure.